To Study the Effects of Host Genetic Factors on Liver Cirrhosis
Preventive and Personalized Medicine (2021-2023)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Bibigul Saparbekovna, PhD
- Phone Number: +77075001190
- Email: fakhradiyev.i@kaznmu.kz
Study Locations
-
-
-
Almaty, Kazakhstan
- National Scientific Center of Surgery named after A.N. Syzganova
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- hepatitis B
Exclusion Criteria:
- the casual aget of liver disease is not viral infection, such as alcohol abuse
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental group:
patients with liver cirrhosis
|
SNP analysis of the DNA obtained from peripheral blood sample
|
|
Control group
patients without liver cirrhosis
|
SNP analysis of the DNA obtained from peripheral blood sample
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
genotyping for the SNP associated with liver cirrhosis
Time Frame: 1 year
|
Genotype frequency of SNP in the study genes of participants and control participants.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bibigul Saparbekovna, PhD, JSC "National Scientific Center of Surgery named after A.N. Syzganova "
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1188
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
NCT03911037UnknownDecompensated Cirrhosis of Liver
-
NCT06293378RecruitingFibrosis, Liver | Cirrhosis, Liver
-
NCT05128578Completed
-
NCT06671275Enrolling by invitation
-
NCT04243681Completed
-
NCT03236090WithdrawnCirrhosis, Liver
-
NCT04149223Recruiting
Clinical Trials on SNP analysis of the DNA
-
NCT05095155Completed
-
NCT05121415Completed
-
NCT05095129Completed
-
NCT05088512CompletedBronchial Asthma | Genome Wide Association Studies
-
NCT05095142Completed
-
NCT01025024CompletedSingle-nucleotide Polymorphism (SNP) for Glaucoma
-
NCT00782366CompletedMyocardial Infarction | Obesity | Breast Cancer | Osteoarthritis | Atrial Fibrillation | Graves Disease | Lung Cancer | Celiac Disease | Prostate Cancer | Colon Cancer
-
NCT03250819CompletedCorticosteroid Induced Ocular Hypertension/Glaucoma
-
NCT03190746CompletedRheumatoid Arthritis